Abstract
In this issue of Blood, Grace et al characterize the clinical manifestations, disease complications, and response to treatment of 278 patients with pyruvate kinase (PK) deficiency from a 5-country longitudinal natural history study. The availability of such a large genetic and clinical data set of patients with this rare red cell disorder will allow for more robust genotype–phenotype correlations and guide the development of future therapeutic strategies.